United Therapeutics Co. (NASDAQ:UTHR - Get Free Report) CEO Martine A. Rothblatt sold 15,000 shares of the company's stock in a transaction on Thursday, April 4th. The shares were sold at an average price of $233.27, for a total transaction of $3,499,050.00. Following the completion of the sale, the chief executive officer now directly owns 130 shares in the company, valued at $30,325.10. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
United Therapeutics Price Performance
Shares of NASDAQ UTHR opened at $233.56 on Friday. The firm has a market capitalization of $10.99 billion, a P/E ratio of 11.77 and a beta of 0.52. United Therapeutics Co. has a one year low of $204.44 and a one year high of $261.54. The company's fifty day moving average is $227.31 and its two-hundred day moving average is $227.80. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.28 and a current ratio of 4.41.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $4.36 EPS for the quarter, beating analysts' consensus estimates of $4.28 by $0.08. The company had revenue of $614.70 million during the quarter, compared to the consensus estimate of $575.01 million. United Therapeutics had a net margin of 42.31% and a return on equity of 17.72%. The company's quarterly revenue was up 25.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.67 EPS. Analysts forecast that United Therapeutics Co. will post 23.46 EPS for the current fiscal year.
Analyst Ratings Changes
Have You Seen Elon’s New A.I. Device? (Picture Inside)
From InvestorPlace | Ad
A strange new era for mankind is upon us...
And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day.
Elon believes A.I. is advancing so fast...
This strange new device to protect us against that A.I. threat...
UTHR has been the subject of a number of research analyst reports. The Goldman Sachs Group upgraded shares of United Therapeutics from a "sell" rating to a "neutral" rating and upped their price objective for the stock from $213.00 to $215.00 in a research report on Monday, February 12th. SVB Leerink initiated coverage on shares of United Therapeutics in a report on Monday, February 5th. They issued an "outperform" rating and a $330.00 price objective for the company. Leerink Partnrs reaffirmed an "outperform" rating on shares of United Therapeutics in a research note on Monday, February 5th. StockNews.com raised shares of United Therapeutics from a "buy" rating to a "strong-buy" rating in a research note on Wednesday. Finally, Wells Fargo & Company increased their price target on shares of United Therapeutics from $309.00 to $325.00 and gave the stock an "overweight" rating in a research report on Thursday, March 7th. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $294.40.
View Our Latest Stock Report on UTHR
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of the business. BlackRock Inc. increased its holdings in shares of United Therapeutics by 5.4% during the first quarter. BlackRock Inc. now owns 4,751,961 shares of the biotechnology company's stock valued at $1,064,249,000 after purchasing an additional 241,594 shares during the period. Vanguard Group Inc. grew its holdings in United Therapeutics by 0.4% during the third quarter. Vanguard Group Inc. now owns 4,662,911 shares of the biotechnology company's stock worth $1,053,212,000 after acquiring an additional 20,373 shares during the period. State Street Corp grew its holdings in United Therapeutics by 4.5% during the second quarter. State Street Corp now owns 1,875,758 shares of the biotechnology company's stock worth $414,074,000 after acquiring an additional 80,656 shares during the period. Wellington Management Group LLP grew its holdings in United Therapeutics by 73.7% during the first quarter. Wellington Management Group LLP now owns 1,675,414 shares of the biotechnology company's stock worth $300,585,000 after acquiring an additional 710,668 shares during the period. Finally, Geode Capital Management LLC raised its holdings in United Therapeutics by 14.9% during the 1st quarter. Geode Capital Management LLC now owns 759,143 shares of the biotechnology company's stock worth $169,811,000 after buying an additional 98,267 shares during the period. 94.08% of the stock is owned by institutional investors and hedge funds.
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
